Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

31 results about "Tizanidine" patented technology

This medication is used to treat muscle spasms caused by certain conditions (such as multiple sclerosis, spinal cord injury).

Delivery of a sympatholytic cardiovascular agent to the central nervous system

A sympatholytic cardiovascular agent delivered by a drug delivery pump to a central nervous system site to alleviate symptoms of acute or chronic cardiac insult or impaired cardiac performance. The drug delivery pump can be external or implantable infusion pump (IIP) coupled with a drug infusion catheter extending to the site. A patient activator can command delivery of a dosage and / or an implantable heart monitor (IHM) coupled with a sensor can detect physiologic parameters associated with cardiac insult or impaired cardiac performance and trigger dosage delivery. The IIP and IHM can be combined into a single implantable medical device (IMD) or can constitute separate IMDs that communicate by any of known communication mechanisms. The sympatholytic cardiovascular agent is one of the group consisting of an alpha-adrenergic agonist and an alpha2-adrenergic agonist (e.g., clonidine, p-aminoclonidine, guanabenz, lidamidine, tizanidine, moxonidine, methyldopa, xylazine, guanfacine, detomidine, medetomidine, and dexmedetomidine).
Owner:MEDTRONIC INC

Delivery of a sympatholytic cardiovascular agent to the central nervous system to counter heart failure and pathologies associated with heart failure

A sympatholytic cardiovascular agent delivered by a drug delivery pump to a central nervous system site to alleviate symptoms and otherwise treat heart failure (HF) and pathologies associated with HF. The drug delivery pump can be external or implantable infusion pump (IIP) coupled with a drug infusion catheter extending to the site. A patient activator can command delivery of a dosage and / or an implantable heart monitor (IHM) coupled with a sensor can detect physiologic parameters associated with HF (or pathologies associated with HF) and trigger dosage delivery. The IIP and IHM can be combined into a single implantable medical device (IMD) or can constitute separate IMDs that communicate by any of known communication mechanisms. The sympatholytic cardiovascular agent is one of the group consisting of an alpha-adrenergic agonist and an alpha2-adrenergic agonist, e.g., clonidine, p-aminoclonidine, guanabenz, lidamidine, tizanidine, moxonidine, methyldopa, xylazine, guanfacine, detomidine, medetomidine, and dexmedetomidine.
Owner:MEDTRONIC INC

Pharmaceutical Compositions and Related Methods of Treatment

InactiveUS20080021074A1Decrease and prevent sleepinessDecrease and prevent and lethargyBiocideNervous disorderAdrenergic receptor agonistsClumsiness
Pharmaceutical compositions comprising at least one alpha2-adrenergic agonist or baclofen and at least one alpha1-adrenergic agonist are disclosed. Pharmaceutical compositions comprising tizanidine and modafinil are disclosed. Methods for reducing somnolence, sleepiness, lethargy, dizziness, drowsiness, somnolence, tiredness, lightheadedness, increased weakness, confusion, unsteadiness, clumsiness, or a combination of the symptoms thereof in a human patient; treating pain; and attenuating muscle spasticity, using pharmaceutical compositions comprising at least one alpha2-adrenergic agonist or baclofen and at least one alpha1-adrenergic agonist are disclosed.
Owner:QUESTCOR PHARMA

Delivery of a sympatholytic cardiovascular agent to the central nervous system

ActiveUS20050177097A1BiocideElectrocardiographyLidamidineCardiac monitoring
A sympatholytic cardiovascular agent delivered by a drug delivery pump to a central nervous system site to alleviate symptoms of acute or chronic cardiac insult or impaired cardiac performance. The drug delivery pump can be external or implantable infusion pump (IIP) coupled with a drug infusion catheter extending to the site. A patient activator can command delivery of a dosage and / or an implantable heart monitor (IHM) coupled with a sensor can detect physiologic parameters associated with cardiac insult or impaired cardiac performance and trigger dosage delivery. The IIP and IHM can be combined into a single implantable medical device (IMD) or can constitute separate IMDs that communicate by any of known communication mechanisms. The sympatholytic cardiovascular agent is one of the group consisting of an alpha-adrenergic agonist and an alpha2-adrenergic agonist (e.g., clonidine, p-aminoclonidine, guanabenz, lidamidine, tizanidine, moxonidine, methyldopa, xylazine, guanfacine, detomidine, medetomidine, and dexmedetomidine).
Owner:MEDTRONIC INC

Extended release alpha-2 agonist pharmaceutical dosage forms

Disclosed is an extended release pharmaceutical formulation containing at least an alpha-2 adrenergic agonist, such as tizanidine, for the treatment and prevention of spasticity in a subject, e.g., painful inflammatory conditions associated with skeletal muscle spasms.
Owner:GLENMARK PHARMACEUTICALS LIMITED

Pharmaceutical formulation containing muscle relaxant and COX-II inhibitor

Disclosed is an extended release pharmaceutical formulation comprising a muscle relaxant drug, such as tizanidine, in combination with a cyclooxygenase-2 inhibitor, such as valdecoxib. The formulations are useful in the treatment and management of painful inflammatory conditions associated with, for example, skeletal muscle spasms.
Owner:GLENMARK PHARMACEUTICALS LIMITED

Tizanidine compositions and methods of treatment using the compositions

InactiveUS20070078174A1Improving daytime quality of lifeImprove sleep qualityBiocideNervous disorderBlood concentrationNervous system
The invention is directed to methods of treating spasticity in patient having a neurological disease comprising administering to a patient in need of such treatment a tizanidine formulation providing a tizanidine blood concentration of at least about 900 pg / ml for about five hours, wherein the formulation is administered prior to bedtime.
Owner:TEVA PHARM USA INC

Zero order controlled release compositions of tizanidine

The present invention relates to a novel controlled release formulations of tizanidine. The invention also provides methods of using novel controlled release formulations of tizanidine to treat a patient.
Owner:ALZA CORP

Controlled release compositions of tizanidine

ActiveUS20080214629A1Increasing plasma tizanidine concentrationBiocideMuscular disorderControlled-Release FormulationsTizanidine
The present invention relates to a novel controlled release formulations of tizanidine. The invention also provides methods of using novel controlled release formulations of tizanidine to treat a patient.
Owner:ALZA CORP

Implantable tizanidine compositions and methods of treatment thereof

A method of treating the symptoms of spasticity comprises implanting a reservoir-based drug delivery composition into a subject to systemically deliver a therapeutically effective amount of tizanidine to the subject for a long period of time (e.g., one month or one year). The drug delivery composition may include a rate-controlling excipient (e.g., an elastomeric polymer) defining a reservoir containing at least one discrete solid dosage form (e.g., one or more pellets), which includes tizanidine free base and optionally, a sorption enhancer.
Owner:BRAEBURN PHARMA INC

Method and compound for treatment of menopausal symptoms

The subject invention describes a method of use of Ropinirole™ to alleviate and control menopausal symptoms in women, and in particular, hot flashes. The invention describes the use of Ropinirole as a dopamine agonist with affinity for the dopamine D2, D3, or D4 receptors. Ropinirole may also be used to treat menopausal symptoms in conjunction with Tizanidine™ to further reduce the effects menopausal symptoms by providing a sedative and muscle relaxant effect which aids in sleep. The combination of Ropinirole and Tizanidine provides a useful new compound for treatment of menopausal symptoms that are most disruptive to the functioning in activities of daily living.
Owner:KNOBLER ROBERT L

Slow release preparation of tizanidine

A slowly-released medicine of tizanidine in the form of dispersing solid is prepared from tizanidine and slow-releasing skeleton.
Owner:刘凤鸣

Implantable tizanidine compositions and methods of treatment thereof

A method of treating the symptoms of spasticity comprises implanting a reservoir-based drug delivery composition into a subject to systemically deliver a therapeutically effective amount of tizanidine to the subject for a long period of time (e.g., one month or one year). The drug delivery composition may include a rate-controlling excipient (e.g., an elastomeric polymer) defining a reservoir containing at least one discrete solid dosage form (e.g., one or more pellets), which includes tizanidine free base and optionally, a sorption enhancer.
Owner:BRAEBURN PHARMA INC

Method of reducing somnolence in patients treated with tizanidine

An article and method for reducing somnolence in a patient receiving tizanidine therapy. Tizanidine may be administered in the form of an immediate release multiparticulate composition at or around the time food is consumed. The composition may be packaged in a container for distribution.
Owner:PELLEGRINI CARA A +1

Tizanidine nitrate crystal form A, and preparation method and applications thereof

The invention provides a tizanidine nitrate crystal form A, and a preparation method and applications thereof. The provided tizanidine nitrate crystal form A uses a Cu-K[alpha] radiation source to perform X-ray powder diffraction, and a 2[theta] diffraction angle has characteristic absorption peaks at 11.4 + / - 0.2, 20.8 + / - 0.2, 21.8 + / - 0.2, 23.2 + / - 0.2 and 26.7 + / - 0.2 degrees; the crystal formA is high in chemical purity, stable in property and low in hygroscopicity, and an effective solution can be provided for the improvement of the availability and security of drugs; and in addition, the crystal form A is simple in preparation technology, short in reaction time and high in product yield, and has no special requirements on equipment, so that the crystal form A is suitable for industrial production.
Owner:SICHUAN CREDIT PHARMA

Pharmaceutical composition of tizanidine and process for preparing the same

InactiveUS20180049989A1Capsule deliveryTizanidineDrug
The present invention relates to a solid oral pharmaceutical composition comprising an effective amount of Tizanidine or its pharmaceutically acceptable salts, esters, solvates, polymorphs, stereoisomers or mixtures thereof. The solid oral dosage form of the present invention is free of non-pareil seeds. The invention also relates to a process for the preparation of a pharmaceutical composition comprising an effective amount of Tizanidine wherein, the dosage form is free of non-pareil seeds.
Owner:JUBILANT GENERICS

Tizanidine p-toluenesulfonate crystal form A and preparation method and applications thereof

The invention provides a tizanidine p-toluenesulfonate crystal form A and a preparation method thereof, and applications. The provided tizanidine p-toluenesulfonate crystal form A uses a Cu-K[alpha] radiation source to perform X-ray powder diffraction, and a 2[theta] diffraction angle has characteristic absorption peaks at 6.7 + / - 0.2, 13.5 + / - 0.2, 20.4 + / - 0.2, 21.4 + / - 0.2 and 24.3 + / - 0.2 degrees. The crystal form A has high product chemical purity, stable properties and low hygroscopicity, and effective solutions can be provided for the improvement of the security and validity of drugs; and in addition, the crystal form A is simple in preparation technology, short in reaction time, high in yield, good in reproducibility and suitable for industrial production.
Owner:SICHUAN CREDIT PHARMA

Method of reducing somnolence in patients treated with tizanidine

An article and method for reducing somnolence in a patient receiving tizanidine therapy. Tizanidine may be administered in the form of an immediate release multiparticulate composition at or around the time food is consumed. The composition may be packaged in a container for distribution.
Owner:KING GEORGE HLDG LUXEMBOURG IIA S A R L
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products